Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 319

Similar articles for PubMed (Select 12394789)

1.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7.

PMID:
12394789
2.

Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.

Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, Liao Q, Hirani A, Graham N, St Clair M, Hernandez J; NZT40012 Study Team.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1107-15.

PMID:
11522180
3.

Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.

Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA; AIDS Clinical Trials Group 302 Study Team.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):377-80.

PMID:
11468426
4.

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.

AIDS. 1999 Apr 16;13(6):685-94.

PMID:
10397563
5.
6.

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.

Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.

HIV Med. 2001 Oct;2(4):231-5.

PMID:
11737402
7.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
8.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
9.

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.

Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.

J Med Virol. 1999 Dec;59(4):507-11.

PMID:
10534734
10.

The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.

Gilleece Y, Torti C, Mandalia S, Gazzard BG, Pillay D, Pozniak AL.

HIV Med. 2003 Oct;4(4):305-10.

PMID:
14525540
11.

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. Erratum in: J Acquir Immune Defic Syndr. 2003 Jan;32(1):116..

PMID:
12473833
12.

Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.

Gallant JE, Chaisson RE, Keruly JC, Moore RD.

AIDS. 1999 Feb 4;13(2):225-9.

PMID:
10202828
13.

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.

Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.

Pediatr Infect Dis J. 2006 Nov;25(11):1049-56.

PMID:
17072129
14.

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.

AIDS. 2003 Sep 5;17(13):1889-96.

PMID:
12960821
15.

Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.

Paolucci S, Baldanti F, Maserati R, Castelli F, Suter F, Maggiolo F, Pan A, Gerna G.

Antiviral Res. 2000 Feb;45(2):101-14.

PMID:
10809019
16.

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team.

AIDS. 2002 Aug 16;16(12):1686-9.

PMID:
12172093
17.
19.

Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.

Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.

J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):465-6. No abstract available.

PMID:
11141248
20.

The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.

Gianotti N, Galli L, Boeri E, De Bona A, Guffanti M, Danise A, Salpietro S, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):447-52.

PMID:
16652052
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk